Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Stewart

Showing results (31-40 of 208) with videos related to

Pageof 21
Sort By:
Blood|March 12, 2005
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myelomaHong Chang, A Keith Stewart, Xiao Ying Qi, et al.
Environmental Science & Technology|May 3, 2017
A Field Trial of TCE Phytoremediation by Genetically Modified Poplars Expressing Cytochrome P450 2E1Emily K Legault, C Andrew James, Keith Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2005
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistanceWilfrid Jaksic, Suzanne Trudel, Hong Chang, et al.
Blood|July 10, 2015
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myelomaA Keith Stewart, Susanna Jacobus, Rafael Fonseca, et al.
Molecular Cancer Research : MCR|June 21, 2020
Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor SensitivityChang-Xin Shi, Yuan Xiao Zhu, Laura A Bruins, et al.
Blood|December 16, 2004
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myelomaSuzanne Trudel, Zhi Hua Li, Ellen Wei, et al.
Mayo Clinic Proceedings|December 14, 2005
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantationYoung Trieu, Suzanne Trudel, Gregory R Pond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2009
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignanciesOwen A O'Connor, A Keith Stewart, Marcy Vallone, et al.
Chest|August 5, 2011
Acute lung toxicity related to pomalidomideHolly L Geyer, Robert W Viggiano, Martha Q Lacy, et al.
Cancer Research|December 8, 2011
Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genomeRodger E Tiedemann, Yuan Xao Zhu, Jessica Schmidt, et al.
Pageof 21

Showing results (31-40 of 208) with videos related to

Sort By:
Pageof 21
Blood|March 12, 2005
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myelomaHong Chang, A Keith Stewart, Xiao Ying Qi, et al.
Environmental Science & Technology|May 3, 2017
A Field Trial of TCE Phytoremediation by Genetically Modified Poplars Expressing Cytochrome P450 2E1Emily K Legault, C Andrew James, Keith Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2005
Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistanceWilfrid Jaksic, Suzanne Trudel, Hong Chang, et al.
Blood|July 10, 2015
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myelomaA Keith Stewart, Susanna Jacobus, Rafael Fonseca, et al.
Molecular Cancer Research : MCR|June 21, 2020
Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor SensitivityChang-Xin Shi, Yuan Xiao Zhu, Laura A Bruins, et al.
Blood|December 16, 2004
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myelomaSuzanne Trudel, Zhi Hua Li, Ellen Wei, et al.
Mayo Clinic Proceedings|December 14, 2005
Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantationYoung Trieu, Suzanne Trudel, Gregory R Pond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 12, 2009
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignanciesOwen A O'Connor, A Keith Stewart, Marcy Vallone, et al.
Chest|August 5, 2011
Acute lung toxicity related to pomalidomideHolly L Geyer, Robert W Viggiano, Martha Q Lacy, et al.
Cancer Research|December 8, 2011
Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genomeRodger E Tiedemann, Yuan Xao Zhu, Jessica Schmidt, et al.
Pageof 21